Correlation Between Kura Oncology and Replimune

Can any of the company-specific risk be diversified away by investing in both Kura Oncology and Replimune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kura Oncology and Replimune into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Kura Oncology and Replimune Group, you can compare the effects of market volatilities on Kura Oncology and Replimune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kura Oncology with a short position of Replimune. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kura Oncology and Replimune.

Diversification Opportunities for Kura Oncology and Replimune

0.58

Correlation Coefficient

Kura Oncology  Replimune

Very weak diversification

The 3 months correlation between Kura and Replimune is 0.58. Overlapping area represents the amount of risk that can be diversified away by holding Kura Oncology and Replimune Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Replimune Group and Kura Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kura Oncology are associated (or correlated) with Replimune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Replimune Group has no effect on the direction of Kura Oncology i.e., Kura Oncology and Replimune go up and down completely randomly.

Pair Corralation between Kura Oncology and Replimune

Given the investment horizon of 90 days Kura Oncology is expected to under-perform the Replimune. But the stock apears to be less risky and, when comparing its historical volatility, Kura Oncology is 1.22 times less risky than Replimune. The stock trades about -0.07 of its potential returns per unit of risk. The Replimune Group is currently generating about -0.05 of returns per unit of risk over similar time horizon. If you would invest  1,233  in Replimune Group on December 29, 2024 and sell it today you would lose (188.00) from holding Replimune Group or give up 15.25% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Kura Oncology  vs.  Replimune Group

Kura Oncology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Kura Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Replimune Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days Replimune Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.

Pair Trading with Kura Oncology and Replimune

The main advantage of trading using opposite Kura Oncology and Replimune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kura Oncology position performs unexpectedly, Replimune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Replimune will offset losses from the drop in Replimune's long position.

The idea behind Kura Oncology and Replimune Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.